CPhI Worldwide to return in 2021

CPhI Worldwide 2021 31 August - 2 September 2021, Milan, Italy.
CPhI Worldwide will be held next year in Milan (Fiera Milano) for the first time in over a decade - following its postponement in 2020. The event returns at an apt moment, as the pharma industry in Italy is anticipated to be one of the main beneficiaries of geo-diverse sourcing strategies.

Italy is Europe's largest producer and exporter of APIs - 85% are exported to North America, the EU and Japan[1] - and the 2020 CPhI Annual Report Survey indicates the country is well set for growth in 2021, as pharma looks for new manufacturing partners. The results show that Italy has improved its 'growth ranking' by 16% in a year - the largest rise of any country - with Western European API manufacturers predicted to be the 'biggest beneficiaries of supply chain changes' by some 47% of respondents.

To further empower the industry's growth, CPhI Worldwide 2021 will implement a 'hybrid event model', featuring onsite exhibition and conference agenda, as well as online sessions and matchmaking. Offering further encouragement for the prospects of attendees, nearly two thirds (61%) of the industry foresees an improved 'business outlook for pharma' in 2021, with 67% 'actively looking for new partners'.

"We are really excited to be hosting the 2021 event in Milan - Europe's largest pharma manufacturing region - especially with Italy seeing the largest reputational and growth increases of any country in our recent executive survey. Pharma manufacturers here, and particularly ingredients producers, are widely expected to see sizable growth rates in 2021, with companies now actively looking to make new contacts, and implement multi-partner sourcing strategies. That’s why meeting new contacts at the event next year will be so important, as it will be the first time the global community has come back together," commented Orhan Caglayan, Brand Director at CPhI Worldwide/Informa.

CPhI Worldwide 2021 in Milan will feature all five co-located events; including P-MEC, FDF, ICSE, BioProduction and Innopack, with Informa's AllSecure Standards implemented - providing the most robust at-event biosafety measures, spanning dozens of special health&safety protocols.

Caglayan added: "CPhI Worldwide is international pharma’s only true one-stop-hub for everything from equipment, generics and packaging through to biologics, ingredients and contract services. We believe that quality of life can be improved through attainable healthcare, delivered by more accessible and affordable medicines. It is why over the last 30+ years we have built a platform to unite the specialist communities improving healthcare - and our role has never been more important as new supply chain partnerships are sought globally. We help accelerate pharma advancement by enabling attendees to meet with not just one or two, but hundreds of potential partners simultaneously. Nowhere else can you do this as well as at CPhI Worldwide and we cannot wait to welcome global pharma to Milan."

For further information, please visit:
https://www.cphi.com/europe/en/home.html

About CPhI

CPhI drives growth and innovation at every step of the global pharmaceutical supply chain from drug discovery to finished dosage. Through exhibitions, conferences and online communities, CPhI brings together more than 100,000 pharmaceutical professionals each year to network, identify business opportunities and expand the global market. CPhI hosts events in Europe, Korea, China, India, Japan, South East Asia, North America, and the Middle East and Africa. Co-locating with ICSE for contract services; P-MEC for machinery, equipment & technology; InnoPack for pharmaceutical packaging; bioLIVE for biopharma; Finished Dosage Formulation for every aspect of the finished dosage supply chain; and NEX for natural extract products, applications and solutions.

About Informa Markets

Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. Our portfolio is comprised of more than 550 international B2B events and brands in markets including Healthcare & Pharmaceuticals, Infrastructure, Construction & Real Estate, Fashion & Apparel, Hospitality, Food & Beverage, and Health & Nutrition, among others. We provide customers and partners around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, specialist digital content and actionable data solutions. As the world's leading exhibitions organizer, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year.

The Informa Markets annual schedule of Pharmaceutical events include: CPhI & P-MEC China 2020 (16-18 December 2020 (Virtual)); CPhI & P-MEC India 2020 (28-29 January 2021 at the India Expo Mart, Greater Noida, Delhi NCR - Delhi, India); CPhI Japan (14-16 April, 2021 at the Big Sight Exhibition Centre - Tokyo, Japan); Pharmapack Europe 2021 (19-20 May, 2021 at the Paris Expo, Porte de Versailles - Paris, France); CPhI and P-MEC China 2021 (22-24 June, 2021 at SNIEC - Shanghai, China); CPhI South East Asia (4-6 August, 2021 at Challenger 2, IMPACT, Muang Thong Thani, Thailand); CPhI North America (10 August - 12 August, 2021 at Pennsylvania Convention Centre - Philadelphia, USA); CPhI Korea (11-13 August 2021), COEX - Seoul, Korea).CPhI, ICSE, P-MEC, FDF, InnoPack Worldwide, BioProduction (31 August - 2 September 2021 at Fiera Milano, Milan); CPhI Middle East & Africa (26-28 September, 2021 at the Riyadh International Convention & Exhibition Center, Riyadh, Saudi Arabia).

1. Italian Pharma Outlook, Tuesday 6th October at the CPhI Festival of Pharma

Most Popular Now

COVID-19 vaccine protection wanes after three mont…

The protection offered by the Oxford-Astra Zeneca COVID-19 vaccine declines after three months of receiving two doses, a study says. The findings - drawn from datasets...

New study adds more evidence for Omicron immune ev…

A new study from Columbia researchers, in collaboration with scientists at the University of Hong Kong, adds more evidence that the omicron variant can evade the immune p...

European Commission grants conditional marketing a…

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announce...

Stopping dementia at the nose with combination of …

Dementia is thought to occur when proteins called amyloid-β, tau, and α-synuclein accumulate in the brain and form oligomers. A research group from the Department of Tran...

Vaxzevria significantly boosted antibody levels ag…

AstraZeneca's Vaxzevria (ChAdOx1-S [Recombinant]) significantly boosted levels of antibodies against the Omicron SARS-CoV-2 variant (B.1.1.529) following a third dose boo...

Treatments in weeks, not months: Scientists develo…

An international team of scientists has created a plan for an accelerated pipeline for developing drug cocktails to battle the COVID-19 pandemic. The pipeline could speed...

Scientists identify antibodies that can neutralize…

An international team of scientists have identified antibodies that neutralize omicron and other SARS-CoV-2 variants. These antibodies target areas of the virus spike pro...

COVID-19 can trigger self-attacking antibodies

Infection with the virus that causes COVID-19 can trigger an immune response that lasts well beyond the initial infection and recovery - even among people who had mild sy...

Leiden University Medical Center and Intravacc to …

Intravacc, a global leader in translational research and development of therapeutic vaccines and vaccines against infectious diseases, today announced a partnership with ...

Pfizer and BioNTech sign new global collaboration …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new research, development and commercialization collaboration to develop a potential first mRNA-based v...

AstraZeneca and Ionis close agreement to develop a…

AstraZeneca has closed a global development and commercialisation agreement with Ionis Pharmaceuticals, Inc. (Ionis) for eplontersen, formerly known as IONIS-TTR-LRX. ...

COVID-19 - Omicron: resistant to most monoclonal a…

The Omicron variant was detected for the first time in South Africa in November 2021 and has since spread to many countries. It is expected to become the dominant variant...